Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will host a conference call and live webcast on February 9, 2022, at 8:30 AM ET to discuss its third quarter fiscal 2022 financial results and operational highlights. Investors can dial in or access the event online. Medicenna is focused on developing immunotherapies like its IL-2 Superkine, MDNA11, and IL-4 Empowered Superkine, MDNA55, which has received Fast-Track and Orphan Drug designations from the FDA. Further information will be made available following the live broadcast.

Positive

• IL-2 Superkine MDNA11 has superior CD122 binding, targeting cancer-killing cells.
• MDNA55 has received Fast-Track and Orphan Drug status, facilitating its development.

Negative

• None.

TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 9, 2022 at 8:30 AM ET to report its third quarter fiscal 2022 financial results and operational highlights.

To access the call, please dial (877) 407-9716 from the Canada and the United States or (201) 493-6779 internationally, followed by the conference ID: 13726690. To access the live webcast, please go visit https://viavid.webcasts.com/starthere.jsp?ei=1526480&tp_key=191321ca33. Following the live webcast, an archived version of the call will be available on Medicenna’s website.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

When is Medicenna's Q3 fiscal 2022 earnings call?

Medicenna's Q3 fiscal 2022 earnings call is scheduled for February 9, 2022, at 8:30 AM ET.

What is Medicenna's stock symbol?

Medicenna's stock symbol is MDNA, listed on both NASDAQ and TSX.

What treatments is Medicenna developing?

Medicenna is developing novel immunotherapies including MDNA11 and MDNA55.

What designations has MDNA55 received?

MDNA55 has received Fast-Track and Orphan Drug designations from the FDA.